SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors
PRRT is a safe treatment option and appears to have a favourable effect in patients with recurrent meningiomas. WHO tumor grade is the strongest predictor of PFS and OS, while baseline PET parameters appear to have no prognostic value.
Authors
- Philipp E. Hartrampf (ORCID: https://orcid.org/0000-0001-5622-9849)
- Andreas K. Buck (ORCID: https://orcid.org/0000-0002-6447-0613)
- Sebastian E. Serfling (ORCID: https://orcid.org/0009-0001-5740-0537)
- Marieke Heinrich
- Rudolf Alexander Werner (ORCID: https://orcid.org/0000-0003-3372-6046)
- Bülent Polat (ORCID: https://orcid.org/0000-0003-4677-424X)
- Kerstin Michalski (ORCID: https://orcid.org/0000-0001-8715-7788)
- Natalie Hasenauer
- Heribert Hänscheid (ORCID: https://orcid.org/0000-0003-1366-911X)
- Miriam Müller
Institutions
- Universitätsklinikum Würzburg (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-06-02
- DOI
- https://doi.org/10.1007/s00259-025-07336-6
- Citations
- 3
- Primary Topic
- Meningioma and schwannoma management
- Type
- article
- Field-Weighted Citation Impact
- 4.06